[Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders].

Abstract

Forty one patients with refractory malignant lymphoma were treated with a combination of VP-16, ACM, BH-AC, MTX and PDN as a salvage chemotherapy. These patients were either resistant to frontline therapy or refractory in their relapses. Three patients (7%) achieved a complete remission and 14 patients (34%) attained a partial remission. An overall response rate was 41%. Major toxicities were myelosuppression, nausea, and vomiting. However, they were well tolerated. This regimen has been effective in the treatment for the patients with refractory malignant lymphoma.

• Authors: E Miyazaki, Y Takemoto, A Kanamaru, E Kakishita, K Nagai, T Masaoka, H Shibata, A Horiuti, K Tsubaki, T Yonezawa
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 19 Issue 4 Pg. 497-503 (Apr 1992) ISSN: 0385-0684 [Print] Japan
• PMID: 1558399 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study)

Chemical References

• Cytarabine
• Etoposide
• Aclarubicin
• Prednisolone
• enocitabine
• Methotrexate

Topics

• Aclarubicin (administration & dosage)
• Adolescent
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cytarabine (administration & dosage, analogs & derivatives)
• Etoposide (administration & dosage)
• Female
• Hodgkin Disease (drug therapy)
• Humans
• Immunoblastic Lymphadenopathy (drug therapy)
• Leukemia-Lymphoma, Adult T-Cell (drug therapy)
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Methotrexate (administration & dosage)
• Middle Aged
• Prednisolone (administration & dosage)